| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jan van Amsterdam, Jojanneke Vervloet, Gerdien de Weert, Victor J A Buwalda, Anna E Goudriaan, Wim van den Brin. Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia. Harm reduction journal. vol 15. issue 1. 2019-02-11. PMID:30236118. |
acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia. |
2019-02-11 |
2023-08-13 |
Not clear |
| Philip McGuire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wrigh. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. The American journal of psychiatry. vol 175. issue 3. 2018-12-27. PMID:29241357. |
cannabidiol (cbd) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. |
2018-12-27 |
2023-08-13 |
Not clear |
| Johannes Rentzsch, Golo Kronenberg, Ada Stadtmann, Andres Neuhaus, Christiane Montag, Rainer Hellweg, Maria Christiane Jockers-Scherüb. Opposing Effects of Cannabis Use on Late Auditory Repetition Suppression in Schizophrenia Patients and Healthy Control Subjects. Biological psychiatry. Cognitive neuroscience and neuroimaging. vol 2. issue 3. 2018-12-19. PMID:29528297. |
opposing effects of cannabis use on late auditory repetition suppression in schizophrenia patients and healthy control subjects. |
2018-12-19 |
2023-08-13 |
human |
| Johannes Rentzsch, Golo Kronenberg, Ada Stadtmann, Andres Neuhaus, Christiane Montag, Rainer Hellweg, Maria Christiane Jockers-Scherüb. Opposing Effects of Cannabis Use on Late Auditory Repetition Suppression in Schizophrenia Patients and Healthy Control Subjects. Biological psychiatry. Cognitive neuroscience and neuroimaging. vol 2. issue 3. 2018-12-19. PMID:29528297. |
nevertheless, the effects of cannabis use on neurocognitive functioning in schizophrenia have remained largely unspecified. |
2018-12-19 |
2023-08-13 |
human |
| Cecilie Bhandari Hartberg, Elisabeth H Lange, Trine Vik Lagerberg, Unn K Haukvik, Ole A Andreassen, Ingrid Melle, Ingrid Agart. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 1. 2018-12-11. PMID:29254657. |
cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. |
2018-12-11 |
2023-08-13 |
Not clear |
| Cecilie Bhandari Hartberg, Elisabeth H Lange, Trine Vik Lagerberg, Unn K Haukvik, Ole A Andreassen, Ingrid Melle, Ingrid Agart. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 1. 2018-12-11. PMID:29254657. |
cannabis is associated with increased risk for severe mental illness and is commonly used among individuals with schizophrenia or bipolar disorder. |
2018-12-11 |
2023-08-13 |
Not clear |
| Cecilie Bhandari Hartberg, Elisabeth H Lange, Trine Vik Lagerberg, Unn K Haukvik, Ole A Andreassen, Ingrid Melle, Ingrid Agart. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 1. 2018-12-11. PMID:29254657. |
in this study we investigated associations between cannabis use and brain structures among patients with schizophrenia or bipolar disorders. |
2018-12-11 |
2023-08-13 |
Not clear |
| Cecilie Bhandari Hartberg, Elisabeth H Lange, Trine Vik Lagerberg, Unn K Haukvik, Ole A Andreassen, Ingrid Melle, Ingrid Agart. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 1. 2018-12-11. PMID:29254657. |
magnetic resonance imaging scans were obtained for 77 schizophrenia and 55 bipolar patients with a history of cannabis use (defined as lifetime use >10 times during one month or abuse/dependence), and 97 schizophrenia, 85 bipolar disorder patients and 277 healthy controls without any previous cannabis use. |
2018-12-11 |
2023-08-13 |
Not clear |
| Cecilie Bhandari Hartberg, Elisabeth H Lange, Trine Vik Lagerberg, Unn K Haukvik, Ole A Andreassen, Ingrid Melle, Ingrid Agart. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 1. 2018-12-11. PMID:29254657. |
the present findings support the understanding that cannabis use is associated with limited brain effects in schizophrenia as well as bipolar disorder. |
2018-12-11 |
2023-08-13 |
Not clear |
| Boris Guennewig, Maina Bitar, Ifeanyi Obiorah, James Hanks, Elizabeth A O'Brien, Dominik C Kaczorowski, Yasmin L Hurd, Panos Roussos, Kristen J Brennand, Guy Barr. THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Translational psychiatry. vol 8. issue 1. 2018-12-11. PMID:29691375. |
there is a strong association between cannabis use and schizophrenia but the underlying cellular links are poorly understood. |
2018-12-11 |
2023-08-13 |
human |
| Brian J Miller, Peter F Buckley, Joseph P McEvo. Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophrenia research. vol 195. 2018-11-26. PMID:28843438. |
we investigated relationships between inflammatory markers, comorbid marijuana and cocaine use, and psychopathology and cognition in patients with schizophrenia. |
2018-11-26 |
2023-08-13 |
Not clear |
| Rachel A Rabin, Karolina Kozak, Konstantine K Zakzanis, Gary Remington, Tony P Georg. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophrenia research. vol 194. 2018-11-13. PMID:28285022. |
effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. |
2018-11-13 |
2023-08-13 |
Not clear |
| Rachel A Rabin, Karolina Kozak, Konstantine K Zakzanis, Gary Remington, Tony P Georg. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophrenia research. vol 194. 2018-11-13. PMID:28285022. |
rates of cannabis use among patients with schizophrenia are high, however little is understood about clinical effects of continued cannabis use and cessation after illness onset. |
2018-11-13 |
2023-08-13 |
Not clear |
| Rachel A Rabin, Karolina Kozak, Konstantine K Zakzanis, Gary Remington, Tony P Georg. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophrenia research. vol 194. 2018-11-13. PMID:28285022. |
therefore, we investigated the effects of 28-days of cannabis abstinence on psychotic and depressive symptomatology in cannabis dependent patients with schizophrenia. |
2018-11-13 |
2023-08-13 |
Not clear |
| Marise W J Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophrenia research. vol 194. 2018-11-13. PMID:28351544. |
comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: a randomized fmri study. |
2018-11-13 |
2023-08-13 |
Not clear |
| Marise W J Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophrenia research. vol 194. 2018-11-13. PMID:28351544. |
cannabis use disorders (cuds) are highly comorbid in patients with schizophrenia and associated with poor outcome. |
2018-11-13 |
2023-08-13 |
Not clear |
| Nicolás Libuy, Valeria de Angel, Carlos Ibáñez, Robin M Murray, Adrian P Mund. The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. Schizophrenia research. vol 194. 2018-11-13. PMID:28427930. |
the relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. |
2018-11-13 |
2023-08-13 |
Not clear |
| Nicolás Libuy, Valeria de Angel, Carlos Ibáñez, Robin M Murray, Adrian P Mund. The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. Schizophrenia research. vol 194. 2018-11-13. PMID:28427930. |
much research has suggested that the use of cannabis increases the risk of schizophrenia; there is less evidence concerning cocaine. |
2018-11-13 |
2023-08-13 |
Not clear |
| Nicolás Libuy, Valeria de Angel, Carlos Ibáñez, Robin M Murray, Adrian P Mund. The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. Schizophrenia research. vol 194. 2018-11-13. PMID:28427930. |
the aim of the present study was to establish the relative prevalence of schizophrenia in people treated for cannabis use and cocaine use disorders in chile. |
2018-11-13 |
2023-08-13 |
Not clear |
| Joshua Chiappelli, Shuo Chen, Ann Hackman, L Elliot Hon. Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population. Schizophrenia research. vol 194. 2018-11-13. PMID:28487076. |
although people diagnosed with schizophrenia are known to have elevated risks of abuse and dependence for nicotine, alcohol, cocaine, and cannabis, it is less clear if schizophrenia is associated with higher rates of opioid use disorders compared to either the general population or individuals with other major psychiatric disorders. |
2018-11-13 |
2023-08-13 |
Not clear |